NOS2 and irritable bowel syndrome: The treatment notably reduces the expression of pro-inflammatory cytokines and key enzymes such as COX-2 and iNOS, contributing to the alleviation of oxidative stress and inflammation in colonic tissues, which are crucial factors in the pathogenesis of IBD.